CoChat

Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development

Open access
Guerlavais, Vincent, Sawyer, Tomi K., Carvajal, Luis, Chang, Yong S., Graves, Bradford, Ren, Jian-Guo, Sutton, David, Olson, Karen A., Packman, Kathryn, Darlak, Krzysztof, Elkin, Carl, Feyfant, Eric, Kesavan, Kamala, Gangurde, Pranoti, Vassilev, Lyubomir T., Nash, Huw M., Vukovic, Vojislav, Aivado, Manuel, Annis, D. Allen · 2023 · Journal of Medicinal Chemistry
Cited by 136

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

We report the discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-helical peptide to enter clinical trials. ALRN-6924 is a “stapled peptide” that mimics the N-terminal domain of the p53 tumor suppressor protein. It binds with high affinity to both MDM2 and MDMX (also known as MDM4), the endogenous inhibitors of p53, to activate p53 signaling in cells having a non-mutant, or wild-type TP53 genotype ( TP53 -WT). Iterative structure–activity optimization endowed ALRN-6924 with favorable cell permeability, solubility, and pharmacokinetic and safety profiles. Intracellular proteolysis of ALRN-6924 forms a long-acting active metabolite with potent MDM2 and MDMX binding affinity and slow dissociation kinetics. At high doses, ALRN-6924 exhibits on-mechanism anticancer activity in TP53 -WT tumor models. At lower doses, ALRN-6924 transiently arrests the cell cycle in healthy tissues to protect them from chemotherapy without protecting the TP53 -mutant cancer cells. These results support the continued clinical evaluation of ALRN-6924 as an anticancer and chemoprotection agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.3c00623

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 136

Metadata

Authors
Guerlavais, V., Sawyer, T. K., Carvajal, L., Chang, Y. S., Graves, B., Ren, J.-G., Sutton, D., Olson, K. A., Packman, K., Darlak, K., Elkin, C., Feyfant, E., Kesavan, K., Gangurde, P., Vassilev, L. T., Nash, H. M., Vukovic, V., Aivado, M., & Annis, D. A.
Venue
Journal of Medicinal Chemistry
Published
2023-07-13
Volume
66
Issue
14
Pages
9401-9417
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4384120632
Cited by
136
References
16
FWCI
10.16
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development. https://app.cochat.ai/papers/10.1021/acs.jmedchem.3c00623
The paper
Guerlavais, V., Sawyer, T. K., Carvajal, L., Chang, Y. S., Graves, B., Ren, J.-G., Sutton, D., Olson, K. A., Packman, K., Darlak, K., Elkin, C., Feyfant, E., Kesavan, K., Gangurde, P., Vassilev, L. T., Nash, H. M., Vukovic, V., Aivado, M., & Annis, D. A. (2023). Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00623

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.